5/23/2022  5:27:49 PM Chg. -1.75 Volume Bid5:35:21 PM Ask5:35:21 PM Market Capitalization Dividend Y. P/E Ratio
491.25GBX -0.35% 17,905
Turnover(GBP): 89,009.0450
-Bid Size: - -Ask Size: - 395.05 mill.GBP - -

Business description

Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.
 

Management board & Supervisory board

CEO
John Dawson
Management board
Stuart Paynter, Helen Stephenson-Ellis, James Miskin, Jason Slingsby, Kyriacos Mitrophanous, Matthew Treagus, Natalie Walter, Nick Page
Supervisory board
Dr. Roch Doliveux, Dr. Michael Hayden, Dr. Sam Rasty, Heather Preston, John Dawson, Prof. Dame Kay Davies, Robert Ghenchev, Stuart Henderson, Stuart Paynter
 

Company data

Name: Oxford BioMedica plc
Address: Windrush Court, Transport Way,UK-Oxford OX4 6LT
Phone: +44-1865-783-000
Fax: +44-1865-783-001
E-mail: enquiries@oxfordbiom...a.co.uk enquiries@oxfordbiomedica.co.uk
Internet: https://www.oxb.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 50.20%
IPO date: -

Investor relations

Name: Catherine Isted
IR phone: -
IR Fax: -
IR e-mail: investor-relations@o...a.co.uk investor-relations@oxfordbiomedica.co.uk

Main Shareholders

Freefloat
 
50.20%
Vulpes Investment Management
 
11.90%
Novo Holdings
 
10.00%
M&G Investments
 
8.70%
Liontrust Asset Management
 
5.00%
Nine Ten Capital
 
3.80%
Hargreaves Lansdown Asset Management
 
3.70%
Mr. S M H Shah
 
3.50%
Artisan Partners
 
3.20%